SG11202002085YA - Neuroactive steroids and their methods of use - Google Patents
Neuroactive steroids and their methods of useInfo
- Publication number
- SG11202002085YA SG11202002085YA SG11202002085YA SG11202002085YA SG11202002085YA SG 11202002085Y A SG11202002085Y A SG 11202002085YA SG 11202002085Y A SG11202002085Y A SG 11202002085YA SG 11202002085Y A SG11202002085Y A SG 11202002085YA SG 11202002085Y A SG11202002085Y A SG 11202002085YA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- neuroactive steroids
- neuroactive
- steroids
- Prior art date
Links
- 150000003431 steroids Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762555404P | 2017-09-07 | 2017-09-07 | |
| US201762595998P | 2017-12-07 | 2017-12-07 | |
| PCT/US2018/050012 WO2019051264A1 (en) | 2017-09-07 | 2018-09-07 | Neuroactive steroids and their methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202002085YA true SG11202002085YA (en) | 2020-04-29 |
Family
ID=63794613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202002085YA SG11202002085YA (en) | 2017-09-07 | 2018-09-07 | Neuroactive steroids and their methods of use |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20200281943A1 (en) |
| EP (1) | EP3678670A1 (en) |
| JP (2) | JP2020533310A (en) |
| CN (2) | CN111491637A (en) |
| AU (1) | AU2018327357A1 (en) |
| CA (1) | CA3075038A1 (en) |
| IL (2) | IL303250A (en) |
| MX (3) | MX2020002652A (en) |
| SG (1) | SG11202002085YA (en) |
| TW (2) | TW202342058A (en) |
| WO (1) | WO2019051264A1 (en) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014169836A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| US9725481B2 (en) | 2013-04-17 | 2017-08-08 | Sage Therapeutics, Inc. | 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof |
| CN117304245A (en) | 2013-04-17 | 2023-12-29 | 萨奇治疗股份有限公司 | 19-nor steroids that stimulate neural activity and methods of use thereof |
| MX362543B (en) | 2013-04-17 | 2019-01-24 | Sage Therapeutics Inc | 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof. |
| SI3021852T1 (en) | 2013-07-19 | 2021-07-30 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| HUE052308T2 (en) | 2013-08-23 | 2021-04-28 | Sage Therapeutics Inc | Neuroactive steroids, compositions, and uses thereof |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| ES2808855T3 (en) | 2014-10-16 | 2021-03-02 | Sage Therapeutics Inc | Compositions and methods for treating CNS disorders |
| TW202235090A (en) | 2014-10-16 | 2022-09-16 | 美商賽吉醫療公司 | Compositions and methods for treating cns disorders |
| PL3224269T3 (en) | 2014-11-27 | 2020-08-24 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| EP3250210B1 (en) | 2015-01-26 | 2020-12-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| US10329320B2 (en) | 2015-02-20 | 2019-06-25 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| DK3481845T3 (en) | 2016-07-11 | 2023-11-27 | Sage Therapeutics Inc | C17, C20 AND C21 SUBSTITUTED NEUROACTIVE STEROIDS AND THEIR METHODS OF USE |
| US20190233465A1 (en) | 2016-07-11 | 2019-08-01 | Sage Therapeutics, Inc. | C7, c12, and c16 substituted neuroactive steroids and their methods of use |
| BR112019003637A2 (en) | 2016-08-23 | 2019-08-06 | Sage Therapeutics Inc | a crystalline c21-n-pyrazolyl 19-nor disubstituted steroid |
| JP2021505608A (en) | 2017-12-08 | 2021-02-18 | セージ セラピューティクス， インコーポレイテッド | Juuterized 21- [4-cyano-pyrazole-1-yl] -19-nor-pregan-3 for treating CNS disorders. α-all-20-one derivative |
| TW202005653A (en) * | 2018-06-12 | 2020-02-01 | 美商賽吉醫療公司 | A 19-NOR C3,3-disubstituted C21-N-pyrazolyl steroid and methods of use thereof |
| CN111454318A (en) * | 2019-01-20 | 2020-07-28 | 浙江易众化工有限公司 | Crystal form of antidepressant SAGE-217 and preparation method thereof |
| CR20210629A (en) * | 2019-05-31 | 2022-03-22 | Sage Therapeutics Inc | Neuroactive steroids and compositions thereof |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| CN114761019A (en) * | 2019-12-05 | 2022-07-15 | 萨奇治疗股份有限公司 | 19-nor C3, 3-disubstituted C21-N-pyrazolylsterols and methods of use thereof |
| WO2021195297A1 (en) | 2020-03-25 | 2021-09-30 | Sage Therapeutics, Inc. | Use of agents for treatment of respiratory conditions |
| CA3187178A1 (en) * | 2020-07-20 | 2022-01-27 | Sage Therapeutics, Inc. | Formulations of 19-nor c3,3- disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
| US20230372365A1 (en) * | 2020-10-01 | 2023-11-23 | Andrew D. Levin | Methods of treating fibromyalgia with neuroactive steroids |
| US20230372364A1 (en) * | 2020-10-01 | 2023-11-23 | Jeremy Hill | Method of treating gaba mediated disorders |
| US11969434B1 (en) | 2022-08-29 | 2024-04-30 | Lipocine Inc. | Oral allopregnanolone compositions and methods of use |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1888080T1 (en) * | 2005-06-09 | 2010-08-31 | Euro Celtique Sa | Pharmaceutical compositions of a neuroactive steroid and uses thereof |
| ES2589139T3 (en) * | 2007-06-15 | 2016-11-10 | Research Triangle Institute | Androstane and pregnan steroids with potent allosteric modulation properties of the GABA / ionophore chloride receptor complex |
| GB201207886D0 (en) * | 2012-05-04 | 2012-06-20 | Jagotec Ag | Improvements in or relating to organic compounds |
| MX362543B (en) * | 2013-04-17 | 2019-01-24 | Sage Therapeutics Inc | 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof. |
| MA43815A (en) * | 2016-03-08 | 2021-04-07 | Sage Therapeutics Inc | NEUROACTIVE STEROIDS, COMPOSITIONS, AND THEIR USES |
| BR112019003637A2 (en) * | 2016-08-23 | 2019-08-06 | Sage Therapeutics Inc | a crystalline c21-n-pyrazolyl 19-nor disubstituted steroid |
-
2018
- 2018-09-07 EP EP18783180.5A patent/EP3678670A1/en active Pending
- 2018-09-07 SG SG11202002085YA patent/SG11202002085YA/en unknown
- 2018-09-07 CN CN201880071392.7A patent/CN111491637A/en active Pending
- 2018-09-07 CN CN202310969827.2A patent/CN117771252A/en active Pending
- 2018-09-07 MX MX2020002652A patent/MX2020002652A/en unknown
- 2018-09-07 US US16/644,680 patent/US20200281943A1/en not_active Abandoned
- 2018-09-07 TW TW112100926A patent/TW202342058A/en unknown
- 2018-09-07 AU AU2018327357A patent/AU2018327357A1/en active Pending
- 2018-09-07 WO PCT/US2018/050012 patent/WO2019051264A1/en unknown
- 2018-09-07 CA CA3075038A patent/CA3075038A1/en active Pending
- 2018-09-07 TW TW107131531A patent/TW201919641A/en unknown
- 2018-09-07 JP JP2020513783A patent/JP2020533310A/en active Pending
- 2018-09-07 IL IL303250A patent/IL303250A/en unknown
-
2020
- 2020-03-05 IL IL273099A patent/IL273099A/en unknown
- 2020-03-06 MX MX2023009611A patent/MX2023009611A/en unknown
- 2020-03-06 MX MX2023009610A patent/MX2023009610A/en unknown
-
2022
- 2022-11-23 US US17/993,020 patent/US20230310459A1/en active Pending
-
2023
- 2023-01-18 JP JP2023005761A patent/JP2023033543A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020533310A (en) | 2020-11-19 |
| AU2018327357A1 (en) | 2020-03-26 |
| TW202342058A (en) | 2023-11-01 |
| IL273099A (en) | 2020-04-30 |
| CN111491637A (en) | 2020-08-04 |
| MX2023009611A (en) | 2023-08-24 |
| US20230310459A1 (en) | 2023-10-05 |
| US20200281943A1 (en) | 2020-09-10 |
| CN117771252A (en) | 2024-03-29 |
| MX2023009610A (en) | 2023-08-24 |
| IL303250A (en) | 2023-07-01 |
| CA3075038A1 (en) | 2019-03-14 |
| JP2023033543A (en) | 2023-03-10 |
| WO2019051264A1 (en) | 2019-03-14 |
| EP3678670A1 (en) | 2020-07-15 |
| TW201919641A (en) | 2019-06-01 |
| MX2020002652A (en) | 2020-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273099A (en) | Neuroactive steroids and their methods of use | |
| IL283629A (en) | Neuroactive steroids and their methods of use | |
| IL286970A (en) | Neuroactive steroids and methods of use thereof | |
| HRP20181994T1 (en) | Neuroactive steroids and methods of use thereof | |
| IL266353A (en) | Steroids and protein-conjugates thereof | |
| HRP20210526T8 (en) | Oxysterols and methods of use thereof | |
| HK1220979A1 (en) | 19-nor neuroactive steroids and methods of use thereof 19- | |
| IL266093A (en) | Oxysterols and methods of use thereof | |
| HK1255500A1 (en) | Oxysterols and methods of use thereof | |
| IL266092B1 (en) | Oxysterols and methods of use thereof | |
| IL256531B (en) | Oxysterols and methods of use thereof | |
| PT3481846T (en) | Oxysterols and methods of use thereof | |
| PT3436022T (en) | Oxysterols and methods of use thereof | |
| IL250270B (en) | Abiraterone acetate formulation and methods of use | |
| IL280082A (en) | Neuroactive steroid solutions and their methods of use | |
| ZA202100093B (en) | Neuroactive steroids and methods of preparation |